Overview
This study aims to compare the nighttime heartburn improvement effect of Tegoprazan 50mg and Esomeprazole 40mg(or 20mg) in patients with GERD.
Description
This is a multi-center, double-blind, randomized, active-controlled phase 4 study. Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 50mg, esomeprazole 40mg or 20mg).
Eligibility
Inclusion Criteria:
- Subjects aged between 19 and 75 years
- Subjects who have erosive reflux disease or non-erosive reflux disease
Exclusion Criteria:
- Unable to undergo upper GI endoscopy
- Symptoms of primary or secondary esophageal movement disorders
- Subjects who have undergone or are scheduled to undergo surgery that can affect gastric acid secretion(e.g. upper gastrectomy, vagotomy, etc)